TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04311437

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-acupressure therapy
Description: The self-acupressure therapy is as follows: Patients are in sitting position, applied firm pressure (3-5 kg of pressure) with the fingertips in a circular motion at a speed of two circles per second for a duration of one min per acupoint. A 1-2-s rest is applied after each ten circles. The complete process lasts for about 5 min.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Combined Valsalva and Toynbee maneuvers
Description: Valsalva maneuver: blowing against a closed mouth and nostrils, increasing the middle ear pressure. Toynbee maneuver: swallowing while the mouth and nostrils are closed, decreasing the middle ear pressure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Valsalva and Toynbee maneuvers
Description: Valsalva maneuver: blowing against a closed mouth and nostrils, increasing the middle ear pressure. Toynbee maneuver: swallowing while the mouth and nostrils are closed, decreasing the middle ear pressure.
Study: NCT03637894

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Feeding infants with fermented formula milk
Description: Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Feeding infants with fermented formula milk
Description: Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Feeding infants with standard formula milk
Description: Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Feeding infants with standard formula milk
Description: Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.

Intervention type: OTHER
Group type: OTHER
Intervention: Breastfeeding infants
Description: Reference group

Intervention type: OTHER
Group type: OTHER
Intervention: Breastfeeding infants
Description: Reference group
Study: NCT01695863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: comparing 2 drugs on their effect on the bowel preparation for colonoscopy
Description: the effects of the drug on the colon preparation for colonoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: comparing 2 drugs on their effect on the bowel preparation for colonoscopy
Description: the effects of the drug on the colon preparation for colonoscopy
Study: NCT01437943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Take 1 tablet (150 mg) by mouth daily for 180 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 1 tablet (0 mg) daily for 180 days.
Study: NCT03102463

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Water Control
Description: 120mL water given as a control, followed by a hyperinsulinemic-euglycaemic clamp

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk derived hydrolysate
Description: Milk derived hydrolysate made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parent Protein
Description: Parent protein made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lipid Load
Description: 100mL oral lipid load

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lipid Load
Description: 100mL oral lipid load

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Lipid Load
Description: 100mL oral lipid load
Study: NCT01577628

Intervention type: DRUG
Group type: OTHER
Intervention: Lipikar Balm AP
Description: Daily application of Lipikar Balm AP starting at birth
Study: NCT03250130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hypnosis
Description: The patient achieve self-hypnosis sessions in these chemotherapy treatments
Study: NCT01751789

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Linkage

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Study: NCT01512693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0822
Description: A single oral dose (50 mg tablet) of MK 0822 will be administered on Day 1 after an overnight fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0822
Description: A single oral dose (50 mg tablet) of MK 0822 will be administered on Day 1 after an overnight fast.
Study: NCT01058057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: atorvastatin 80mg p.o. daily seven days before PCI
Study: NCT03317912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaïne 2%
Description: Continuous infusion during per and postoperative periods

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Lidocaïne)
Description: Continuous infusion during per and postoperative periods
Study: NCT02823613

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High salt diet followed by low salt diet
Description: High salt diet (250 mmol/day) in 5 days followed by low salt diet (60-70 mmol/day) in 5 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low salt diet followed by high salt diet
Description: Low salt diet (60-70 mmol/day) in 5 days followed by high salt diet (250 mmol/day) in 5 days.
Study: NCT04597515

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot Breast reduction surgery
Description: Breast reduction surgery, using a robot by removing a breast disc at the base
Study: NCT02400060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive text messaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03077555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoely
Description: quick start of combined hormonal contraception containing 1.5 mg estradiol /2.5 mg nomegestrol acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meliane ED
Description: quick start of combined hormonal contraception containing 20 mcg ethinyl estradiol /75 mcg gestodene
Study: NCT00000259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 15 % Nitrous oxide
Study: NCT03154190

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Undergo health care coach support

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT04086589

Intervention type: OTHER
Intervention: Observational study without intervention
Description: Observational study without intervention

Intervention type: OTHER
Intervention: Observational study without intervention
Description: Observational study without intervention
Study: NCT03525873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participate in physical activity

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical Activity
Description: Participate in physical activity

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03520790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Paricalcitol (IV or oral) is a man-made form of vitamin D. It is thought to work by blocking a signal in the cancer tumor cells that leads to growth and spreading of the tumor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Paricalcitol (IV or oral) is a man-made form of vitamin D. It is thought to work by blocking a signal in the cancer tumor cells that leads to growth and spreading of the tumor.
Study: NCT00000259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3 % Sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% Nitrous oxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.6% Sevoflurane

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01264536

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lactoferrin
Description: Infants will receive oral bovine lactoferrin (200 mg/Kg/day divided in three dosis) for 4 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum lactoferrin concentration will be 25mg/mL.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Infants will receive oral maltodextrin (200mg/Kg/day in three divided dosis) for 4 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum maltodextrin concentration will be 25mg/mL.
Study: NCT02498106

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Orthica Soft Multi Mini and Orthica Fish EPA Mini
Description: daily intake of 2 Orthica Soft Multi Mini capsules (containing vitamins \[B1, B2, B3, B5, B6, B11, B12, C, D, E, Beta Carotene\] and minerals \[Iodine, Copper, Selenium, Iron, Zinc, Chrome, Manganese\]) and 1 Orthica Fish EPA Mini capsule (containing n-3FA: eicosapentaenic acid \[EPA\] and docosahexaenic acid \[DHA\])

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Orthica Soft Multi Mini and Orthica Fish EPA Mini
Description: daily intake of 2 Orthica Soft Multi Mini capsules (containing vitamins \[B1, B2, B3, B5, B6, B11, B12, C, D, E, Beta Carotene\] and minerals \[Iodine, Copper, Selenium, Iron, Zinc, Chrome, Manganese\]) and 1 Orthica Fish EPA Mini capsule (containing n-3FA: eicosapentaenic acid \[EPA\] and docosahexaenic acid \[DHA\])
Study: NCT02003521

Intervention type: DEVICE
Intervention: Lung Flute
Description: A low frequency wave is generated at the mouth by exhaling through a mouthpiece over a laminar surface (Reed) inside the Lung Flute®. The resulting low frequency acoustic wave that is produced travels retrograde into the lower airways and lung parenchyma and increases mucociliary clearance. Patients expel air with the force required to blow out a single candle. Patients concentrate on producing a low tone through the device while breathing in a proscribed pattern. Twenty repetitions of a single two-breath pattern are performed with the device to complete a diagnostic session.
Study: NCT02565173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabodenoson 4.5% BID
Description: Trabodenoson 4.5% administered twice per day in both eyes for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabodenoson 6.0% QD
Description: Trabodenoson 6.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabodenoson 3.0% QD
Description: Trabodenoson 3.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol 0.5% BID
Description: Timolol 0.5% administered twice per day in both eyes for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo BID
Description: Placebo administered twice per day in both eyes for 12 weeks.
Study: NCT01635218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic treatment
Description: A single dose of the individualized homeopathic remedy in C-potency was dissolved in a 60 ml bottle of 30% alcohol-distilled water:15 drops PO two times per day following agitation plus fluoxetine-dummy loaded PO daily during 6 weeks. The homeopathic remedy could be changed at every follow-up (week 4) according to patient´s symptoms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: 20 mg per day PO during 6 weeks plus individualized homeopathic dummy-loaded (60 bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic dummy-loaded was repeated at week 4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fluoxetine placebo (capsules containing sucrose microgranules) PO daily during 6 weeks plus individualized homeopathic placebo (60 ml bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic placebo was repeated at week 4.
Study: NCT01455311

Intervention type: PROCEDURE
Intervention: EUS Guided Fine Needle Aspiration
Description: EUS-guided fine needle aspiration of the cyst fluid

Intervention type: PROCEDURE
Intervention: EUS Guided EchoBrush Sampling
Description: EUS-guided brushing of the cyst wall
Study: NCT01470495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RFA + Sorafenib
Description: combined RFA and Sorafenib to treat recurrent HCC
Study: NCT03520790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT00741104

Intervention type: DRUG
Intervention: Infliximab
Description: Treatment of RA with Infliximab according to and under normal routine clinical practice.
Study: NCT03556982

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-123 cells
Description: CD123-Targeted CAR-T cells are infused to patient received FC chemotherapy
Study: NCT03185923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM plus conventional drug
Description: All patients were treated with antibiotics according to international guidelines. The Experimental group will receive TCM according to the TCM syndrome.~qingfeijieduhuatan granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome in 28 treatment days.~zaoshihuatanxiefei granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome in 28 treatment days.~qingxinkaiqiao granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome in 28 treatment days.~shenmai injection（Sichuan chuanda west China Pharmaceutical Co., Ltd.）,15ml/ ampulla, 10～60ml each time (when needed), for yin exhausted syndrome in 28 treatment days.~shenfu injection（Sanjiu Medical \& Pharmaceutical Co., Ltd.）,10ml/ ampulla, 50～100ml each time (when needed), for yang exhausted syndrome in 28 treatment days.
Study: NCT02246621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anastrozole
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT03185923

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TCM placebo plus conventional drug
Description: All patients were treated with antibiotics according to international guidelines. The control group will receive TCM placebo according to the TCM syndrome.~placebo qingfeijieduhuatan granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome every day in 28 treatment days.~placebo zaoshihuatanxiefei granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome every day in 28 treatment days.~placebo qingxinkaiqiao granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome every day in 28 treatment days.
Study: NCT02481791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil and/or propofol
Description: Induction Phase: A dose of remifentanil 1mcg/kg by slow bolus, will be given to facilitate endotracheal intubation. Further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given to ensure an anaesthetised patient.
Study: NCT04689204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTA30X
Description: CTA30X cell injection by intravenous infusion
Study: NCT04350138

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Group B Vaccine
Description: A combination vaccine consisting of rMenB and OMV NZ.
Study: NCT02481791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil and/or propofol
Description: Settling Period: An infusion of the test dose of remifentanil will be commenced from an infusion prepared prior to the patient being anaesthetised. 1mg of Remifentanil (one vial) will be diluted to a volume of 50mls in normal saline 0.9% in a 50ml syringe. Maintenance dose of propofol 130 mcg/Kg/min for the first 5 minutes reduced to 100 mcg/kg/min thereafter. 40mls of propofol 1% (10mg/ml) will be drawn undiluted into a 50ml syringe. During the settling period further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given.
Study: NCT04350138

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150mM sodium chloride (0.9% saline solution).
Study: NCT02998528

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified days
Study: NCT02481791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Equilibrium Period: During this period propofol will be infused at a constant rate of 100mcg/kg/min
Study: NCT00831857

Intervention type: OTHER
Intervention: 89Zr-Bevacizumab PET-scan
Description: At baseline, after two weeks of treatment and after 6 weeks of treatment.

Intervention type: OTHER
Intervention: 89Zr-Bevacizumab PET-scan
Description: At baseline, after two weeks of treatment and after 6 weeks of treatment.
Study: NCT02443051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: Computer delivered modification in 80% of trials

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Bias Modification
Description: Computer delivered modification in 80% of trials
Study: NCT02774291

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IVPB

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02187224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Progesterone)
Study: NCT04134377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein Food Snack
Description: The intervention is 6-months using a food snack with control being three months prior to and three months after-study invention whereby serum albumin levels will be collected monthly. If patients are participating in a supplement program, they will be maintained throughout all ten months of the study so long as the criteria for the supplement program (enrollment and discontinuation) is still being met.